KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Sarepta Therapeutics (SRPT) over the last 16 years, with Dec 2024 value amounting to $124.8 million.

  • Sarepta Therapeutics' Cash from Financing Activities fell 956.22% to -$117.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$80.1 million, marking a year-over-year decrease of 203.07%. This contributed to the annual value of $124.8 million for FY2024, which is 0.16% down from last year.
  • Sarepta Therapeutics' Cash from Financing Activities amounted to $124.8 million in FY2024, which was down 0.16% from $125.0 million recorded in FY2023.
  • Over the past 5 years, Sarepta Therapeutics' Cash from Financing Activities peaked at $682.3 million during FY2020, and registered a low of $124.8 million during FY2024.
  • In the last 3 years, Sarepta Therapeutics' Cash from Financing Activities had a median value of $125.0 million in 2023 and averaged $160.8 million.
  • As far as peak fluctuations go, Sarepta Therapeutics' Cash from Financing Activities grew by 6.19% in 2020, and later tumbled by 58.60% in 2022.
  • Over the past 5 years, Sarepta Therapeutics' Cash from Financing Activities (Yearly) stood at $682.3 million in 2020, then dropped by 17.70% to $561.6 million in 2021, then slumped by 58.60% to $232.5 million in 2022, then tumbled by 46.24% to $125.0 million in 2023, then decreased by 0.16% to $124.8 million in 2024.